Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Omega Funds
Deal Size : $177.0 million
Deal Type : Series A Financing
Antares Launches with $177M to Develop Precision Cancer Medicines
Details : The financing aims to advance the company's preclinical assets to the clinical stage, which are being evaluated for the treatment of cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Omega Funds
Deal Size : $177.0 million
Deal Type : Series A Financing